Report ID :10085398 |
Published Date : 21 Oct 2022 |
Report Format : |
Delivery Timeline :48-72 Business Hours
Global In Vitro Toxicology Testing Market – Drivers, Restraints, Opportunities, Trends, and Forecast: 2018–2024
Overview: In vitro toxicology involves the study of cells or tissues grown or maintained in precise lab conditions to observe the toxic properties of the compound. These testing methods help in inspecting the toxicity of xenobiotics at the cellular level in the laboratory without the interaction of complex physiological systemic effects that are often observed in living organisms. In vitro methods are commonly used in recent years as these can be correlated with in vivo studies and assist in understanding a particular in vivo response in any animal species. It is commonly employed by the pharmaceutical, chemical, food, cosmetic, medical device, and diagnostics industries to test the safety (toxicity) and efficacy of drugs, chemicals, biochemicals, materials, and preparations. Most of the information about the potential toxicity of drug substances are obtained from using animal models, but these tend to have significant limitations when translating them to human risk assessment. Although some basic toxicity testing using human cells in vitro is already a conventional method, many toxicologists are developing more sophisticated in vitro analyses using human-based cell models that can be more predictive about human health outcomes.
The market for in vitro toxicology testing is driven by high opposition to animal testing, increased cost related to animal-based toxicity testing, and increasing R&D expenditure for early stage toxicity testing. Whereas, the lack of in vitro models and decreased adoption rate are limiting the growth of the market to an extent.
Market Analysis: The “global in vitro toxicology testing market” is estimated to witness a CAGR of 8.2% during the forecast period 2018–2024. The global market is analyzed based on three segments – toxicology endpoints, industry type, and regions.
Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (ROW). Europe is the major shareholder in the global in vitro toxicology testing market, followed by North America. The upsurge in the investments by the European Commission in R&D to develop substitute methods to in vivo testing is driving the demand in this region. Asia Pacific is expected to grow at a high CAGR during the forecast period due to increasing number of contract research organizations offering testing services, advancements in healthcare infrastructure, increasing investments in the biopharmaceutical sector, and upward economic conditions in this region.
Toxicology Endpoints Analysis: The in vitro toxicology testing market, by toxicology endpoints, is segmented into systemic toxicity, cytotoxicity testing, genotoxicity testing, ocular toxicity, organ toxicity, dermal toxicity, neurotoxicity, and others. Among these, systemic toxicity accounted for the highest market share in 2017 due to the availability of a wide range of sub-studies, which ensure total analysis of toxicity and safety margin of the testing compounds.
Industry Type Analysis: The in vitro toxicology testing market, by industry type, is segmented into pharmaceutical and biopharmaceutical, cosmetics, chemical, diagnostics, and food industry. The pharmaceutical and biopharmaceutical industry occupied significant market share in 2017 and the cosmetics industry is expected to hold a higher percentage during the forecast period. Increased support of regulatory authorities to use in vitro and in silico methods instead of animal testing to check toxicology is driving the growth of the cosmetic industry.
Key Players:
Laboratory Corporation of America Holdings, Charles River Laboratories, Inc., Bio-Rad Laboratories, GE Healthcare, Thermo Fisher Scientific, Eurofins Scientific, SGS SA, BioIVT, Agilent Technologies, Inc., Abbott Laboratories, Gentronix Limited, Promega Corporation, MB Research Laboratories, Evotec AG (Cyprotex plc), Catalent, Inc., Qiagen N.V., and niche players.
Competitive Analysis: There is an increase in collaborations between companies on in vitro testing of compounds. For instance, in December 2016, Evotec and Celgene entered into a drug discovery collaboration for neurodegenerative diseases. According to agreement terms, Celgene will use Evotec's unique induced pluripotent stem cell (iPSC) platform that enables systematic drug screening in patient-derived disease models. In June 2017, Censo Biotechnologies Ltd. collaborated with Evotec AG to source and provide patient-derived induced pluripotent stem cells to support Evotec’s drug discovery iPSC platform. In addition, the companies are also coming up with new products for in vitro testing. For instance, in January 2018, STEMCELL Technologies Inc. released two product lines for organoid research that will enable scientists to create powerful models for studying human disease in the lab.
Benefits: The report provides complete details about the services offered by in vitro toxicology testing companies in various therapeutic verticals and regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player’s initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.
Key Stakeholders:
Why Choose Kenneth Research ?
-
Insight with Impact : We don’t just gather data — we uncover stories, trends, and opportunities that fuel business growth.
-
Experts Who Get It : Our team speaks your industry’s language and knows what really matters to your customers and market.
-
Custom-Built for You : Forget one-size-fits-all. We craft research and consulting solutions as unique as your business vision.
-
Partners, Not Just Providers : We work with you, not for you — collaborating closely to turn insights into smart, strategic moves.
-
Results That Speak : Our work powers brands, startups, and industry leaders alike — with a track record of ideas that work in the real world.
